Talaporfin - Meiji Seika Pharma
Alternative Names: Aptocine; Laserphyrin; Leserfin; Litx; LS 11; ME 2906; Mono-L-aspartyl chlorin e6; MR 901; NP e6; NPE 6; Talaporfin sodium; Taporfin sodiumLatest Information Update: 30 Apr 2021
Price :
$50 *
At a glance
- Originator Meiji Seika Kaisha
- Developer Light Sciences Oncology; Meiji Seika Pharma; The Childrens Hospital of Philadelphia
- Class Antineoplastics; Porphyrins; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Glioma; Lung cancer; Oesophageal cancer
- Discontinued Age-related macular degeneration; Benign prostatic hyperplasia; Cardiovascular disorders; Colorectal cancer; Liver cancer; Neurofibromatosis 1; Prostate cancer
Most Recent Events
- 08 Apr 2021 Discontinued - Phase-I/II for Liver cancer in Taiwan (IV)
- 08 Apr 2021 Discontinued - Phase-II for Benign prostatic hyperplasia in Australia (IV)
- 08 Apr 2021 Discontinued - Phase-II for Benign prostatic hyperplasia in New Zealand (IV)